Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
This is according to two studies of real-world use of the hepatitis C regimen.
Stop me if you’ve heard this one before.
The pharmaceutical company’s grant-making arm is teaming up with Marshall Health to address areas hit hardest by opioids.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
Zepatier (grazoprevir/elbasvir) is approved to treat those with genotypes 1 and 4 of hepatitis C virus.
Cure rates were near 100 percent even though the population in the study’s analysis had high rates of other health conditions.
A recent analysis of data from a roster of clinical trials yielded reassuring findings for this group of women who have hepatitis C.
In a recent trial, 12 weeks of the drug combination worked well regardless of whether individuals had drug-resistant virus.
The drugmaker is accused of infringing on a patent held by rival Merck & Co. over its formulas for Sovaldi and Harvoni treatment.
A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC
Merck’s hepatitis C treatment cured almost all those with stages 3 through 5 of chronic kidney disease in a VA database.
The company has partnered with the American Liver Foundation to host a series of veteran-specific education workshops across the country.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.